Analyst Ritu Baral of TD Cowen maintained a Buy rating on Vera Therapeutics, boosting the price target to $73.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ritu Baral has given her Buy rating due to a combination of factors including an optimistic outlook on Vera Therapeutics’ financial projections and strategic developments. The company has increased its estimated gross annual pricing for atacicept in IgAN to $350,000, which is significantly higher than previous estimates, driven by new competitor pricing. This adjustment has led to an increase in the projected peak sales in the US to $1.64 billion by 2033, prompting an upward revision of the price target to $73.
Furthermore, Vera Therapeutics is making promising advancements in its clinical pipeline, particularly with the ongoing Phase 2b PIONEER basket study. This study is expanding into new cohorts and indications, potentially broadening the market for atacicept. The company is also exploring a monthly dosing regimen, which could enhance patient compliance and marketability. These strategic initiatives, along with the potential for a mid-year 2026 PDUFA decision, contribute to the positive outlook and the Buy rating.
In another report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a $99.00 price target.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VERA in relation to earlier this year.